Predictive Biomarkers for Immune-Related Endocrinopathies following Immune Checkpoint Inhibitors Treatment
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Predictive Biomarkers for Immune-Related Endocrinopathies following Immune Checkpoint Inhibitors Treatment
Authors
Keywords
-
Journal
Cancers
Volume 15, Issue 2, Pages 375
Publisher
MDPI AG
Online
2023-01-06
DOI
10.3390/cancers15020375
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Association of Antithyroid Antibodies in Checkpoint Inhibitor–Associated Thyroid Immune–Related Adverse Events
- (2022) Christopher A Muir et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Eosinophil counts can be a predictive marker of immune checkpoint inhibitor-induced secondary adrenal insufficiency: a retrospective cohort study
- (2022) Shinobu Takayasu et al. Scientific Reports
- Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1
- (2022) John A. McCulloch et al. NATURE MEDICINE
- Hypereosinophilia is a predictive biomarker of immune checkpoint inhibitor-induced hypopituitarism in patients with renal cell carcinoma
- (2022) Hodaka Yamada et al. BMC Endocrine Disorders
- Human Leukocyte Antigens and Biomarkers in Type 1 Diabetes Mellitus Induced by Immune-Checkpoint Inhibitors
- (2022) Hidefumi Inaba et al. Endocrinology and Metabolism
- Diabetes mellitus induced by immune checkpoint inhibitors: type 1 diabetes variant or new clinical entity? Review of the literature
- (2021) V. Lo Preiato et al. REVIEWS IN ENDOCRINE & METABOLIC DISORDERS
- Higher baseline TSH levels predict early hypothyroidism during cancer immunotherapy
- (2021) C. Luongo et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- Immune-Related Adverse Events (irAE) in Cancer Immune Checkpoint Inhibitors (ICI) and Survival Outcomes Correlation: To Rechallenge or Not?
- (2021) Heidar J. Albandar et al. Cancers
- Mechanistic insights into immune checkpoint inhibitor-related hypophysitis: a form of paraneoplastic syndrome
- (2021) Keitaro Kanie et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Endocrine complications of immunotherapies: a review
- (2021) Rosie Hattersley et al. CLINICAL MEDICINE
- Thyroid immune-related adverse events following immune checkpoint inhibitor treatment
- (2021) Christopher A Muir et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Anti-pituitary antibodies and susceptible human leukocyte antigen alleles as predictive biomarkers for pituitary dysfunction induced by immune checkpoint inhibitors
- (2021) Tomoko Kobayashi et al. Journal for ImmunoTherapy of Cancer
- A Severe Case of Diabetic Ketoacidosis and New-Onset Type 1 Diabetes Mellitus Associated with Anti-Glutamic Acid Decarboxylase Antibodies Following Immunotherapy with Pembrolizumab
- (2021) Sonya K. Kedzior et al. American Journal of Case Reports
- Quantitative imaging biomarkers of immune-related adverse events in immune-checkpoint blockade-treated metastatic melanoma patients: a pilot study
- (2021) Nežka Hribernik et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update
- (2021) Bryan J. Schneider et al. JOURNAL OF CLINICAL ONCOLOGY
- Intestinal Microbiome Associated With Immune-Related Adverse Events for Patients Treated With Anti-PD-1 Inhibitors, a Real-World Study
- (2021) Wenhui Liu et al. Frontiers in Immunology
- Anti-thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-programmed cell death-1 antibodies: a prospective study
- (2020) Norio Okada et al. BRITISH JOURNAL OF CANCER
- Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune‐checkpoint inhibitors
- (2020) Chiaki Kurimoto et al. CANCER SCIENCE
- Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis
- (2020) Xiaoxiang Zhou et al. BMC Medicine
- Human leucocyte antigen DR15, a possible predictive marker for immune checkpoint inhibitor–induced secondary adrenal insufficiency
- (2020) Seiichi Yano et al. EUROPEAN JOURNAL OF CANCER
- Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls
- (2020) Eli P. Darnell et al. Current Oncology Reports
- Predicting development of ipilimumab-induced hypophysitis: utility of T4 and TSH index but not TSH
- (2020) M. S. Siddiqui et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- Immune-related adverse events of checkpoint inhibitors
- (2020) Manuel Ramos-Casals et al. Nature Reviews Disease Primers
- The Resistance Mechanisms of Checkpoint Inhibitors in Solid Tumors
- (2020) Evangelos Koustas et al. Biomolecules
- Multiorgan Immune-Related Adverse Events During Treatment With Atezolizumab
- (2020) Ganessan Kichenadasse et al. Journal of the National Comprehensive Cancer Network
- Baseline serum TSH levels predict the absence of thyroid dysfunction in cancer patients treated with immunotherapy
- (2020) L. Brilli et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non–Small Cell Lung Cancer
- (2020) Bairavi Shankar et al. JAMA Oncology
- A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors
- (2019) Jeroen de Filette et al. HORMONE AND METABOLIC RESEARCH
- BASELINE TSH LEVEL IS ASSOCIATED WITH RISK OF ANTI PD-1 INDUCED THYROID DYSFUNCTION
- (2019) Rena M. Pollack et al. Endocrine Practice
- A comprehensive meta-analysis of endocrine immune-related adverse events of immune checkpoint inhibitors and outcomes in head and neck cancer and lung cancer.
- (2019) Cristiane Jeyce Gomes-Lima et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparative analysis of human leucocyte antigen between idiopathic and anti‐PD‐1 antibody induced isolated adrenocorticotropic hormone deficiency: A pilot study
- (2019) Hidefumi Inaba et al. CLINICAL ENDOCRINOLOGY
- Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities
- (2019) Salahaldin A. Tahir et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
- (2019) Satya Das et al. Journal for ImmunoTherapy of Cancer
- New insight in endocrine-related adverse events associated to immune checkpoint blockade
- (2019) Giusy Elia et al. BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
- Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors
- (2018) Angeliki M. Stamatouli et al. DIABETES
- Biomarker definitions and their applications
- (2018) Robert M Califf EXPERIMENTAL BIOLOGY AND MEDICINE
- Delayed Autoimmune Toxicity Occurring Several Months After Cessation of Anti‐PD‐1 Therapy
- (2018) Sagun Parakh et al. ONCOLOGIST
- Fall in thyroid stimulating hormone (TSH) may be an early marker of ipilimumab-induced hypophysitis
- (2018) Sunita M. C. De Sousa et al. Pituitary
- Combining Immunotherapy and Radiotherapy for Cancer Treatment: Current Challenges and Future Directions
- (2018) Yifan Wang et al. Frontiers in Pharmacology
- Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer
- (2018) Koji Haratani et al. JAMA Oncology
- Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens
- (2018) Romualdo Barroso-Sousa et al. JAMA Oncology
- Association of anti-thyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab
- (2018) Shiro Kimbara et al. CANCER SCIENCE
- Endocrine toxicity of cancer immunotherapy targeting immune checkpoints
- (2018) Lee-Shing Chang et al. ENDOCRINE REVIEWS
- Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy
- (2018) Yiyi Yan et al. Frontiers in Immunology
- Diabetes mellitus induced by PD-1 and PD-L1 inhibitors: description of pancreatic endocrine and exocrine phenotype
- (2018) Lucien Marchand et al. ACTA DIABETOLOGICA
- Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors
- (2018) Emma C. de Moel et al. Cancer Immunology Research
- Profiling Preexisting Antibodies in Patients Treated With Anti–PD-1 Therapy for Advanced Non–Small Cell Lung Cancer
- (2018) Yukihiro Toi et al. JAMA Oncology
- Immune-related eosinophilia induced by anti-programmed death 1 or death-ligand 1 antibodies
- (2017) Alice Bernard-Tessier et al. EUROPEAN JOURNAL OF CANCER
- Association of Serum Anti-GAD Antibody and HLA Haplotypes with Type 1 Diabetes Mellitus Triggered by Nivolumab in Patients with Non–Small Cell Lung Cancer
- (2017) Yuko Usui et al. Journal of Thoracic Oncology
- Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors
- (2017) Adam Diehl et al. Oncotarget
- Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
- (2017) Vivek Kumar et al. Frontiers in Pharmacology
- Antibody-Mediated Thyroid Dysfunction During T-cell Checkpoint Blockade in Patients with Non-Small Cell Lung Cancer
- (2016) J.C. Osorio et al. ANNALS OF ONCOLOGY
- Management of toxicities of immune checkpoint inhibitors
- (2016) Lavinia Spain et al. CANCER TREATMENT REVIEWS
- Immune-related adverse events with immune checkpoint blockade: a comprehensive review
- (2016) J.M. Michot et al. EUROPEAN JOURNAL OF CANCER
- Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events
- (2016) Elisa González-Rodríguez et al. ONCOLOGIST
- Fulminant type 1 diabetes mellitus with anti-programmed cell death-1 therapy
- (2016) Masahide Okamoto et al. Journal of Diabetes Investigation
- Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma
- (2013) Antoni Ribas et al. JOURNAL OF CLINICAL ONCOLOGY
- Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial†
- (2012) M. Reck et al. ANNALS OF ONCOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- What are biomarkers?
- (2010) Kyle Strimbu et al. Current Opinion in HIV and AIDS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now